磺胺嘧啶银治疗烧伤创面102例疗效观察

目的 观察磺胺嘧啶银治疗烧伤创面的效果.方法 采用磺胺嘧啶银治疗大面积深度烧伤及暴露部位烧伤患者102例,男56例,女46例,年龄1～47岁,烧伤面积0.5%～51%,烧伤深度均在浅Ⅱ°和Ⅲ°之间.患者均在烧伤后第1天开始使用磺胺嘧啶银治疗.结果 浅Ⅱ度创面73例均在伤后8～12 d痊愈,无1例发生感染和创面加深,平均...     

中西医结合治疗大面积深度烧伤残余创面

目的：比较中西医结合换药与应用SD-Ag治疗深度烧伤残余创面的临床效果。方法：128例大面积深度烧伤后残余创面患者随机分为两组,治疗组70例中药浸泡,采用中西药联合换药;对照组58例采用洗必泰溶液清洁创面,外涂SD-Ag。结果：与对照组比较,治疗组止痛效果明显,创面愈合时间明显缩短（P〈0.05）;创面愈合2周后,治疗组瘢痕出现率（15例,21.4%）明显少于对照组（35例,60.3%）（P〈0.05）。结论：中西医结合治疗大面积深度烧伤残余创面,具有愈合快、疼痛轻、瘢痕少、住院时间短等优点。     

硝酸银软膏对Ⅱ度烧伤创面治疗作用的多中心临床研究

目的观察硝酸银(AgNO3)软膏对浅Ⅱ、深Ⅱ度烧伤创面的治疗效果,并评价其药物不良反应。方法选择80例浅Ⅱ度和40例深Ⅱ度烧伤患者,进行多中心、随机、阳性药物平行对照和同体试验研究(共4个中心,每个中心30例)。将患者创面按用药不同分为AgNO3组和磺胺嘧啶银(SD-Ag)组,观察各组创面完全愈合时间、指定时相点下创面愈合率、创面细菌培养情况、药物疗效和安全性、药物对创面的刺激性等。结果浅Ⅱ度创面:AgNO3组完全愈合时间为(9．5±2．7)d, SD-Ag组为(10．8±3．4)d,用药后7 d创面愈合率分别为(77．9±20．5)％及(67．3±22．6)％;深Ⅱ度创面:AgNO3组完全愈合时间为(21．5±4．8)d,SD-Ag组为(23．3±6,4)d,用药后20 d创面愈合率分别为(86．6±15．9)％及(78．5±17．7)％。同等深度烧伤创面上述各项数据两组间比较,差异均有统计学意义(P<0．01)。同等深度烧伤创面AgNO3组与SD-Ag组比较,具有同样明显的杀菌作用,但前者对创面的刺激性更小。结论AgNO3软膏是一种可用于浅Ⅱ、深Ⅱ度烧伤创面的有效、安全的外用药。     

纳米银敷料在修复Ⅱ度烧伤创面的应用研究

目的观察纳米银敷料在Ⅱ度烧伤创面的防治感染作用及对创面愈合时间的影响。方法将Ⅱ度(深、浅)烧伤创面患者随机分为纳米银敷料组(A组,65例),1%磺胺嘧啶银霜组(B组,63例)和凡士林油纱组(C组,63例)。创面敷料或用药每天更换1次,使用前后进行创面细菌培养,观察创面愈合时间并进行统计学比较。结果在防治创面细菌定植方面,治疗后创面细菌培养阳性率A组(0%)与B组(1·6%)相似,均较治疗前下降,而C组治疗后细菌培养阳性率(14·3%)较治疗前(4·8%)明显增加。A组浅Ⅱ度创面愈合时间为(9·6±1·6)d,与B、C两组比较均明显提前(P<0·01);A组深Ⅱ度创面愈合时间为(19·1±2·6)d,与C组比较差异具有统计学意义(P<0·01),与B组比较差异无统计学意义(P>0·05)。结论Ⅱ度烧伤创面应用纳米银敷料,可以降低患者创面感染的风险,缩短创面愈合时间。     

应用磺胺嘧啶银软膏面膜治疗面部烧伤创面

面部为暴露部位,烧伤发生率较高,治疗时多采用暴露疗法,即用磺胺嘧啶银(SD Ag)软膏外涂创面,3次/d,换药时再将残留的药膏清除。此操作较繁琐,药物难以涂抹均匀。为此笔者制作了“SD Ag软膏面膜”用以治疗面部烧伤创面,效果较好。该“面膜”是根据患者面部创面形状用单层大张无菌纱布剪制而成,预留双眼、鼻、口等处的开口,在纱布上均匀涂布SD Ag软膏。它可根据用量一次性制备,存好备用。使用时将其覆盖于面部创面上并用压舌板轻轻按压,使之紧贴于创面,不留空隙。每次换药时只需将“面膜”轻轻揭掉,创面经简单处理后,再覆以新的“面膜”。…     

复方磺胺嘧啶锌涂膜剂治疗小儿Ⅱ度烧伤创面的疗效观察

目的总结复方磺胺嘧啶锌涂膜剂与磺胺嘧啶银霜剂对小儿Ⅱ度烧伤创面疗效的观察。方法将104例Ⅱ度烧伤的患儿随机分为观察组和对照组,每组52例。观察组使用复方磺胺嘧啶锌涂膜剂治疗,对照组使用磺胺嘧啶银霜剂治疗,比较两组治疗效果及不良反应发生情况。结果观察组创面平均愈合时间明显短于对照组,观察组创面细菌培养转阴率高于对照组,两组比较差异有统计学意义(P0.05)。治疗过程中两组均无不良反应发生。结论复方磺胺嘧啶锌涂膜剂治疗小儿烧伤创面,具有控制创面感染快、愈合时间短、不良反应无增加等特点,值得临床推广。     

浸浴结合银离子敷料治疗大面积烧伤患者残余创面的疗效

目的 观察浸浴结合银离子敷料治疗大面积烧伤患者残余创面的疗效. 方法 2008年1月-2012年2月笔者单位收治90例大面积烧伤后期残余创面患者,按照随机数字表法分为对照组45例和试验组45例,对照组患者浸浴后创面外用磺胺嘧啶银纱布处理,试验组患者浸浴后以银离子敷料覆盖创面.用药后21 d,评定2组患者的治愈率.观察治疗过程中患者的不良反应.用药前及用药后7、14、21 d,分离与鉴定细菌,并计算创面细菌清除率.对数据进行x2检验和t检验.结果 用药后21 d,对照组与试验组患者的创面治愈率分别为62.22％(28/45)、86.67％(39/45),组间比较差异有统计学意义(x 2=7.067,P＜0.05).用药后2组患者均未见明显不良反应.用药前及用药后7、14 d,2组患者均检出金黄色葡萄球菌、表皮葡萄球菌、铜绿假单胞菌、大肠埃希菌等.试验组患者用药后7、14 d细菌清除率分别为50.0％、71.4％,明显高于对照组(x2值分别为8.067、5.896,P＜0.05或P＜0.01).用药后21 d,2组患者细菌清除率均为100.0％. 结论 浸浴疗法结合银离子敷料治疗烧伤后残余创面能有效控制创面感染,显著提高治愈率.     

湿润烧伤膏治疗烧伤晚期残余创面33例

大面积深度烧伤晚期,往往易发生感染,起水泡等原因造成残余创面,经久不愈较难处理。我院近3年采用MEBO治疗33例烧伤晚期残余创面疗效满意,现报告如下。 1 临床资料 1.1 一般资料:本组33例,男21例,女12例,年龄最大     

Comparison of silver nylon wound dressing and silver sulfadiazine in partial burn wound therapy

The study aims to perform a comparative assessment of two types of burn wound treatment. To do the assessment, patients with partial thickness burn wounds with total body surface area <40% were simple randomised to treat with nanocrystalline silver nylon wound dressing or silver sulfadiazine cream. Efficacy of treatment, use of analgesics, number of wound dressing change, wound infection and final hospitalisation cost were evaluated. The study showed silver nylon wound dressing significantly reduced length of hospital stay, analgesic use, wound infection and inflammation compared with silver sulfadiazine.     

外用富林蜜凝胶治疗烧伤残余创面的多中心临床试验

目的 评价富林蜜凝胶在烧伤患者残余创面中的应用价值. 方法 2011年11月一2012年5月,选择6家笔者单位的60例烧伤残余创面患者进行多中心、随机、自身对照临床试验.将每例患者的2个残余创面按照随机数字表法分为治疗组与对照组,治疗组使用富林蜜凝胶处理,对照组采用碘伏纱布处理.用药后7、14 d比较2组创面的愈合率,并统计完全愈合创面数量;以视觉模拟评分法(VAS)评价患者每次换药的疼痛主诉,统计0分、大于0分且小于或等于3分、大于3分且小于或等于6分、大于6分且小于或等于10分的平均创面数量;统计2组创面的细菌检出情况并观察治疗过程中患者的不良反应.对数据进行重复测量方差分析、t检验、x 2检验或非参数秩和检验.结果 用药后7d,治疗组与对照组创面愈合率分别为(67±24)％和(45±25)％;用药后14 d,治疗组与对照组创面愈合率分别为(92±16)％和(72±23)％,组间比较差异有统计学意义(F=32.388,P ＜0.01).用药后7d,治疗组和对照组分别有10、4个残余创面愈合,组间比较差异无统计学意义(x2 =0,P＞0.05);用药后14 d,治疗组和对照组累计分别有42、7个残余创面愈合,组间比较差异有统计学意义(x 2 =42.254,P＜0.01).治疗组37个创面换药时患者感到轻微疼痛,VAS评分为大于0分且小于或等于3分;对照组43个创面换药时患者感到明显疼痛,VAS评分为大于3分且小于或等于6分,组间各级疼痛评分的平均创面数量比较,差异有统计学意义(Z=-4.638,P＜0.01).2组创面换药过程中检出的细菌包括金黄色葡萄球菌、铜绿假单胞菌、肺炎克雷伯菌、大肠杆菌、鲍氏不动杆菌、表皮葡萄球菌,组间比较差异无统计学意义(x2=0.051,P＞0.05).患者在用药过程中无不良反应. 结论 富林蜜凝胶可以显著促进烧伤残余创面愈合,明显减轻患者的疼痛.     

A randomized comparative trial between Acticoat and SD-Ag in the treatment of residual burn wounds, including safety analysis

OBJECTIVE: To investigate and evaluate the clinical efficacy and safety of Acticoat with nanocrystalline silver for external use on the management of the residual wounds post-burn. METHODS: One hundred and sixty-six wounds of 98 burn patients were enrolled and divided into Acticoat group and silver sulfadiazine group in the multi-center randomized clinical trial. Acticoat was used as the treated group for those who have redness, swelling, and excessive secretion ("heavy" exudates) in the wound, Acticoat was changed once a day. When there is not much secretion in the wound, or redness and swelling were not obvious, the dressings were changed once every 3 days. Silver sulfadiazine (SD-Ag) was used as control group, which was treated under the usual clinical routine. Healing time was observed up to 20 days. Healing percentage on the 15th day after treatment was determined. RESULTS: Healing time was 12.42+/-5.40 days after the application of Acticoat. This was significantly shorter than that of control wounds. The wounds of the trial group healed nearly 3.35 days earlier than the control ones. Healing percentage at 15 days in the trial wounds was 97.37%, which was higher than the control, but there was no significant difference between them. The bacterial clearance rate of the Acticoat group on the 6th and 12th day post-treatment was 16.67 and 26.67%, respectively, which was significantly higher than the control. CONCLUSIONS: Acticoat with nanocrystalline silver promotes the healing process of residual wounds post-burn effectively. No adverse reaction of Acticoat was found during the study.     

Randomised clinical trial of Hydrofiber dressing with silver versus povidone-iodine gauze in the management of open surgical and traumatic wounds

This prospective, randomised clinical trial compared pain, comfort, exudate management, wound healing and safety with Hydrofiber dressing with ionic silver (Hydrofiber Ag dressing) and with povidone-iodine gauze for the treatment of open surgical and traumatic wounds. Patients were treated with Hydrofiber Ag dressing or povidone-iodine gauze for up to 2 weeks. Pain severity was measured with a 10-cm visual analogue scale (VAS). Other parameters were assessed clinically with various scales. Pain VAS scores decreased during dressing removal in both groups, and decreased while the dressing was in place in the Hydrofiber Ag dressing group (n = 35) but not in the povidone-iodine gauze group (n = 32). Pain VAS scores were similar between treatment groups. At final evaluation, Hydrofiber Ag dressing was significantly better than povidone-iodine gauze for overall ability to manage pain (P < 0.001), overall comfort (P < or = 0.001), wound trauma on dressing removal (P = 0.001), exudate handling (P < 0.001) and ease of use (P < or = 0.001). Rates of complete healing at study completion were 23% for Hydrofiber Ag dressing and 9% for povidone-iodine gauze (P = ns). No adverse events were reported with Hydrofiber Ag dressing; one subject discontinued povidone-iodine gauze due to adverse skin reaction. Hydrofiber Ag dressing supported wound healing and reduced overall pain compared with povidone-iodine gauze in the treatment of open surgical wounds requiring an antimicrobial dressing.     

A prospective,randomized trial of silver containing hydrofiber dressing versus 1% silver sulfadiazine for the treatment of partial thickness burns

Silver sulfadiazine has been used as a topical burn wound treatment for many years. Pain associated with dressing changes is a common problem in burn wounds. Aquacel Ag, a hydrofiber dressing coated with ionic silver has been reported to reduce burn wound infection and promote antimicrobial activity. The purpose of this study was to show the benefits of Aquacel Ag for the treatment of partial thickness burns. This prospective randomized study was conducted in 70 patients who had partial thickness burns less than 15% of total body surface area and were treated at Siriraj outpatient burn clinic during December 2006–February 2008. Patients were divided into two groups: Aquacel Ag‐treated group with dressing changes every 3 days (35 patients) and 1% silver sulfadiazine‐treated group, with daily dressing changes (35 patients). There was no difference in demographic data including age, gender, burn percentage between groups. Time‐to‐wound healing pain score during dressing change and cost of treatment were compared between both groups. Time‐to‐wound closure was significantly shorter in the Aquacel Ag‐treated group (10 ± 3 versus 13.7 ± 4 days, P < 0·02) as well as pain scores at days 1, 3 and 7 (4·1 ± 2·1, 2·1 ± 1·8, 0·9 ± 1·4 versus 6·1 ± 2·3, 5·2 ± 2·1, 3·3 ± 1·9, respectively, P < 0·02). Total cost of treatment was 52 ± 29 US dollars for the Aquacel Ag‐treated group versus 93 ± 36 US dollars for the silver sulfadiazine‐treated group. This study showed that Aquacel Ag increased time to healing, decreased pain symptoms and increased patient convenience because of limiting the frequency of replacement of the dressing at lower total cost. This study confirms the efficacy of Aquacel Ag for the treatment of partial thickness burns at an outpatient clinic.     

银离子藻酸盐敷料在儿童四肢深II度烧伤创面中的应用效果观察

目的:探讨藻酸盐银离子敷料治疗儿童深II度烧伤创面中临床效果.方法:选取2015年7月—2016年5月我院烧伤整形科收治的四肢深II度烧伤患儿共60例,随机分为观察组和对照组.在创面清创后,观察组外用藻酸盐银离子敷料覆盖,无菌纱布包扎;对照组采用银锌霜皮肤黏膜抗菌剂涂抹,无菌纱布包扎.两组均根据创面渗出情况换药.比较两组患儿的换药次数、入院第7天的发热率、创面愈合率及愈合时间.结果:与对照组相比,观察组换药次数(8.63±2.37)次,明显少于对照组(14.70±2.30)次,差异有统计学意义(P<0.05).观察组治疗第7天患儿发热率为6.67%(2例),明显低于对照组23.33%(7例),差异有统计学意义(P<0.05);观察组治疗第7、11、15和19天创面愈合率明显高于对照组,差异有统计学意义(P<0.05);观察组创面愈合时间为(20.70±2.30)d,住院时间为(21.33±3.67)d,均较对照组[(27.63±3.63)d和(28.30±3.30)d]缩短,差异具有统计学意义(P<0.05).结论:应用银离子藻酸盐敷料治疗儿童四肢深II度烧伤创面能减少换药次数,加速创面愈合,减少患者痛苦,值得推广和应用.     

A systematic review of silver-containing dressings and topical silver agents (used with dressings) for burn wounds

Silver preparations are commonly used for burns, but evidence of their effectiveness remains poorly defined. The aim of the study was to evaluate the effectiveness of silver-containing dressings and topical silver for preventing infection and promoting healing in burns wounds through a meta-analysis of the available evidence. The Cochrane Central Register of Controlled Trials and relevant databases were searched. Drug companies and experts in this field were also contacted. Randomised controlled trials (RCTs) of silver dressings or topical silver (used with dressings) compared with non-silver dressings were eligible for inclusion. We identified 14 RCTs involving 877 participants. One small trial of a silver-containing dressing showed significantly better healing time compared to the control [MD -3.6; 95% CI -4.94 to -2.26 for partial thickness burns and MD -3.9; 95% CI -4.54 to -3.26 for superficial burns]. Topical silver showed significantly worse healing time compared to the non-silver group [WMD 3.96; 95% CI 2.41-5.51] and showed no evidence of effectiveness in preventing wounds infection [WMD 2.48; 95% CI 0.39-15.73]. Our review suggests that silver-containing dressings and topical silver were either no better or worse than control dressings in preventing wound infection and promoting healing of burn wounds.     

The safety of nanocrystalline silver dressings on burns: a study of systemic silver absorption

INTRODUCTION: Wound dressings containing silver have been in widespread use for many years. However, there are few quantitative data on the systemic absorption of silver or whether there is associated clinical risk. OBJECTIVES: To assess systemic silver levels when Acticoat dressings containing nanocrystalline silver were used, and to determine whether increases in such levels were associated with haematological or biochemical indicators of toxicity. METHOD: A prospective, single-centre, open-label study of 30 patients with relatively small burns that required skin grafting. Serum silver levels were measured before, during and at discontinuation of the use of the Acticoat dressings, and again at 3 and 6 months following completion of treatment. RESULTS: The median total postoperative wound size was 12% of the total body surface area. The median time to maximum silver levels was 9 days. The median maximum serum silver level was 56.8 microg/l. The median serum level at 6 months was 0.8 microg/l. There were no haematological or biochemical indicators of toxicity associated with the silver absorption observed in this study. CONCLUSION: This study has confirmed our view that Acticoat products are safe for use on burns and they remain a standard part of treatment at our centre.